Introduction {#sec1}
============

Asthma is a chronic inflammation disease with an accompanying, increased bronchial sensitivity. The frequency of asthma in Poland is estimated at 10.6% \[[@cit0001]\]. Direct and indirect annual costs of asthma treatment in the European Union are estimated at EUR 30 billion.

The appropriate pharmacotherapy allows obtaining control over asthma and minimizes its impact on patients' daily functioning \[[@cit0002]\]. The occurrence of asthma in patients with various comorbidities deteriorates their quality of life \[[@cit0003]\] and increases not only the frequency of the disease exacerbations \[[@cit0004]\] but also the rate of death in the period of 30 days following the hospitalization due such to exacerbations \[[@cit0005]\]. In this group, comorbidities such as: chronic bronchitis, chronic obstructive pulmonary disease (COPD), chronic sinusitis, stomach ulcers, cardiovascular disease, osteoporosis, diabetes, depression and cancer are more frequent than in the general population \[[@cit0006]--[@cit0009]\]. However, the most common comorbidities observed in patients with asthma are other allergic diseases such as allergic rhinitis and conjunctivitis \[[@cit0010], [@cit0011]\]. Chronic sinusitis is more frequent among patients with severe asthma than in those suffering from its mild form \[[@cit0012]\]. Asthma is also a risk factor for COPD development. It is estimated that the coexistence of COPD occurs in 20% of patients diagnosed with asthma and that the likelihood of this coexistence increases with age \[[@cit0013]\]. The deterioration of the ventilation parameters in older patients is an independent risk factor for fatal cardiovascular events \[[@cit0014]\]. Also, the risk of hypertension \[[@cit0015]\] and ischemic brain events \[[@cit0016]\] is increased in patients with asthma. Furthermore, a higher prevalence of asthma is observed among patients with obesity and type 2 diabetes \[[@cit0017]--[@cit0021]\]. In addition the sleep apnoea syndrome, gastroesophageal reflux disease and depression were shown to increase the frequency of asthma exacerbations \[[@cit0019]--[@cit0024]\].

According to the GINA recommendations, the severity of asthma should determine the selection of pharmacotherapy, while the difficulties in asthma control, despite intensification of pharmacotherapy, should encourage the search for concomitant diseases as well as the lack of compliance.

The COPD is a chronic disease, characterized by long-lasting bronchial obstruction accompanied by a chronic inflammatory response to toxic molecules and gases \[[@cit0025], [@cit0026]\]. The frequency of COPD, confirmed by spirometry, is 8.9% in the population aged over 40 years old \[[@cit0026]\], with the disease's morbidity increasing over time \[[@cit0027]\]. It is estimated that COPD will be the third most common cause of death in 2020 \[[@cit0028]\]. The comorbidities such as type 2 diabetes and ischemic heart disease are the cause of increased frequency of COPD exacerbations necessitating hospitalization \[[@cit0029]\]. In addition, an increased frequency of both depression and anxiety was found among COPD patients \[[@cit0030]\]. Moreover, the anxiety associated with dyspnoea is an independent risk factor for hospitalization in COPD exacerbations \[[@cit0031], [@cit0032]\], while depression is a risk factor for death in patients with COPD \[[@cit0031], [@cit0032]\]. Therefore, the choice of pharmacotherapy in COPD patients should be based on the COPD category in accordance with the GOLD recommendations, but also individualized taking into account other contraindications.

The frequency of allergic rhinitis is estimated at 5--17% in children aged 6--7 years old \[[@cit0033]\]. According to other studies, yearly allergic rhinitis occurred in 2.1% of children and 3.0% of adults, whereas seasonal in 8.9% of children and 8.7% of adults \[[@cit0034]--[@cit0037]\]. It has been shown that both direct and indirect costs associated with allergic rhinitis are high \[[@cit0038]\]. The disease does not cause serious complications but it does deteriorate the quality of life as well as decreases the productivity at work \[[@cit0039], [@cit0040]\]. It should be noted that among patients with allergic rhinitis, the occurrence of asthma is higher than in the general population. Therefore, the effective treatment of allergic rhinitis is crucial.

As mentioned above, the clinical course of asthma and COPD may be modified by comorbidities. Thus, an individual pharmacotherapy strategy should be considered. There are no data assessing the doctors' therapeutic preferences in patients with asthma, COPD or allergic rhinitis and comorbidities. Moreover, there are no data on the impact of the current GINA \[[@cit0041]\], GOLD \[[@cit0042]\] and allergic rhinitis recommendations on these preferences.

Aim {#sec2}
===

Therefore, the aim of the study was the assessment of doctors' preferences in pharmacotherapy of asthma, COPD or allergic rhinitis in relation to concomitant diseases.

Material and methods {#sec3}
====================

In this observational survey, 11,310 outpatients with asthma, COPD or allergic rhinitis were interviewed nationwide by 319 general practitioners, pulmonologists, allergists, laryngologists and paediatricians from March to November 2016. Doctors participating in the study were recruited by medical representatives. Characteristics of the surveyed population are summarized in [Table 1](#t0001){ref-type="table"}.

###### 

Characteristics of doctors participating in the study (*N* = 319)

  Variable                                                                                                                         Result
  -------------------------------------------------------------------------------------------------------------------------------- ------------
  Specialization, *n* (%):                                                                                                         
   Family medicine                                                                                                                 16 (5.0)
   Pulmonology                                                                                                                     210 (66.0)
   Allergology                                                                                                                     64 (20.0)
   Laryngology                                                                                                                     3 (1.0)
   Paediatrics                                                                                                                     26 (8.0)
  Internship, *n* (%) \[years\]:                                                                                                   
   ≤ 10                                                                                                                            0 (0)
   11--15                                                                                                                          13 (4.0)
   16--20                                                                                                                          46 (14.0)
   \> 20                                                                                                                           260 (82.0)
  Basic work place, *n* (%):                                                                                                       
   Public hospital                                                                                                                 76 (24.0)
   Private hospital                                                                                                                0 (0)
   Public outpatient clinic                                                                                                        160 (50.0)
   Private clinic                                                                                                                  57 (18.0)
   Private outpatient practice                                                                                                     26 (8.0)
  Place in which the doctor works, *n* (%):                                                                                        
   Rural                                                                                                                           3 (1.0)
   Town ≤ 200 000 residents                                                                                                        192 (60.0)
   City \> 200 000 residents                                                                                                       124 (39.0)
  The most frequent therapeutic decisions taken in patients with asthma, *n* (%):                                                  
   Short-acting inhaled β~2~-mimetic                                                                                               128 (40.0)
   Inhaled glucocorticosteroids                                                                                                    268 (84.0)
   Antileukotriene                                                                                                                 51 (16.0)
   Long-acting inhaled β~2~-mimetic                                                                                                61 (19.0)
   Long-acting anticholinergic                                                                                                     0 (0)
   Theophylline                                                                                                                    0 (0)
   Oral glucocorticosteroids                                                                                                       0 (0)
   Antibody anti-IgE                                                                                                               0 (0)
  The most important factors influencing these therapeutic decisions, *n* (%):                                                     
   Patient age                                                                                                                     83 (26.0)
   Recommendations GINA taking into account the severity of the disease                                                            277 (87.0)
   Occurrence of concomitant diseases                                                                                              115 (36.0)
   Interactions with other drugs                                                                                                   112 (35.0)
   Impact on quality of life                                                                                                       179 (56.0)
  The most frequent therapeutic decisions taken in patients with COPD, *n* (%):                                                    
   Anticholinergic                                                                                                                 156 (49.0)
   Short-acting inhaled β~2~-mimetic                                                                                               83 (26.0)
   Inhaled glucocorticosteroids                                                                                                    32 (10.0)
   Long-acting inhaled β~2~-mimetic                                                                                                188 (59.0)
   Theophylline                                                                                                                    6 (2.0)
   Oral glucocorticosteroids                                                                                                       0 (0)
   Indacaterol                                                                                                                     3 (1.0)
   Inhibitor of phosphodiesterase 4                                                                                                6 (2.0)
  The most important factors influencing these therapeutic decisions, *n* (%):                                                     
   Patient age                                                                                                                     121 (38.0)
   GOLD recommendations taking into account the severity of the disease                                                            265 (83.0)
   Occurrence of concomitant diseases                                                                                              128 (40.0)
   Interactions with other drugs                                                                                                   96 (30.0)
   Impact on quality of life                                                                                                       156 (49.0)
  Frequent therapeutic decisions taken in patients with allergic rhinitis, *n* (%):                                                
   Antihistamine I generation                                                                                                      19 (6.0)
   Antihistamine II generation                                                                                                     150 (47.0)
   Antihistamine III generation                                                                                                    260 (80.0)
   Drugs reducing nasal congestion                                                                                                 93 (29.0)
   Nasal glucocorticosteroids                                                                                                      297 (93.0)
  The most important factors influencing these therapeutic decisions, *n* (%):                                                     
   Patient age                                                                                                                     115 (36.0)
   Speed of the drug                                                                                                               160 (50.0)
   Safety of use                                                                                                                   239 (75.0)
   Efficacy                                                                                                                        268 (84.0)
   Severity of symptoms                                                                                                            239 (75.0)
   Minimal effect on the central nervous system                                                                                    160 (50.0)
   Interactions with other drugs                                                                                                   131 (41.0)
   Comorbidities                                                                                                                   105 (33.0)
   Effect of the treatment on quality of life                                                                                      179 (56.0)
  The effect of diagnosis of other chronic disease on modification of treatment for asthma or COPD or allergic rhinitis, *n* (%)   258 (81.0)
   Reducing the dose of the drug used, *n* (%)                                                                                     29 (9.0)
   Increasing the dose of the drug used, *n* (%)                                                                                   16 (5.0)
   Changing the current drug used to a preparation of another group, *n* (%)                                                       118 (37.0)
   Adding another drug, *n* (%)                                                                                                    38 (12.0)
   Withdrawal of a previously used drug, *n* (%)                                                                                   57 (18.0)

The two-part questionnaire consisted of several dichotomous and multiple choice questions. The first part of the questionnaire included the doctor's demographic data (specialization, internship, place of work) and question about therapeutic decisions taken in patients with asthma, COPD and allergic rhinitis with comorbidities, as well as factors determining these decisions.

The second part of the questionnaire included the patient's demographic data (gender, age, place of residence, education level) and clinical data: primary diagnosis (asthma/COPD/allergic rhinitis), disease duration, severity of the disease (for asthma: controlled asthma, partially controlled asthma/uncontrolled asthma according to GINA; for COPD: category from A to D according to GOLD; for allergic rhinitis: mild/moderate/severe), treatment used due to primary disease (divided into groups of drugs, depending on the primary diagnosis), comorbidities (allergic rhinitis, allergic conjunctivitis, chronic sinusitis, gastroesophageal reflux disease, overweight, obesity, type 1 and type 2 diabetes, sleep apnoea syndrome, COPD, depression, hypertension, ischaemic heart disease, other diseases on the basis of an ICD-10 code), and comorbidities medication.

Statistical analysis {#sec3.1}
--------------------

The statistical analysis was performed using the Statistica 10.0 PL (Cracow, Poland) software package. Variable values were presented as percentages and mean values with standard deviations (SD). Separate groups were compared using the χ^2^ and χ^2^ for trend tests. A *p* \< 0.05 was considered as statistically significant.

Results {#sec4}
=======

Characteristics of doctors participating in this study {#sec4.1}
------------------------------------------------------

The group of participating doctors was dominated by pulmonologists and allergists (66% and 20%, respectively), working mainly in public outpatient clinics and hospitals in towns and cities. Eighty-two percent of doctors were working for more than 20 years ([Table 1](#t0001){ref-type="table"}).

The therapeutic decision declared by doctors {#sec4.2}
--------------------------------------------

Inhaled glucocorticosteroids and short-acting β~2~-agonist were most commonly used by patients with asthma. Antileukotriene drugs and inhaled long-acting β~2~-agonist were also frequently used. The most important factors influencing the doctors' therapeutic decisions were the GINA recommendations taking into consideration the disease's severity, the impact of the treatment on the patient's quality of life, and the comorbidities and drug interactions ([Table 1](#t0001){ref-type="table"}).

In the population of patients with COPD, inhaled long-acting β~2~-agonists and cholinolytics were most commonly used, followed by short-acting β~2~-agonists. The severity of the disease, impact of the treatment on the quality of life, and comorbidities and patient's age were all taken into account in addition to GOLD recommendations in the decision making ([Table 1](#t0001){ref-type="table"}).

In the population of patients with allergic rhinitis, nasal glucocorticosteroids and antihistamine III generation drugs were most commonly used. The most important factors influencing the treatment decisions were the efficacy, safety, and severity of the symptoms. Furthermore, comorbidities were determined as a very important factor influencing the therapeutic decisions for approximately 1/3 of doctors and as an important factor for 55% of doctors ([Table 1](#t0001){ref-type="table"}).

The therapeutic decision taken in patients with asthma, COPD and allergic rhinitis and reported comorbidities {#sec4.3}
-------------------------------------------------------------------------------------------------------------

Thirty-seven percent of doctors declared that a diagnosis of *de novo* comorbidities most frequently resulted in a change of the used drug to a different one from another group, however cases of drug discontinuation or introduction were also common ([Table 1](#t0001){ref-type="table"}).

Inhaled glucocorticosteroids were most commonly used in the treatment of asthma despite the co-occurrence of hypertension, type 2 diabetes, cardiovascular diseases and sleep apnoea ([Table 2](#t0002){ref-type="table"}). However, the usage frequency of this drug was slightly decreased in such groups in favour of the increased usage of long-acting β~2~-mimetics in comparison to the above described declaration related to the general population diagnosed with asthma. Similarly, in the treatment of COPD with comorbidities, inhaled long-acting β~2~-mimetics were most commonly used ([Table 2](#t0002){ref-type="table"}). Nevertheless, in groups with comorbidities the use of inhaled short-acting β~2~-mimetics was increased in comparison to the above-described declaration related to the general population with COPD. In the treatment of allergic rhinitis, independently of comorbidities, nasal glucocorticosteroids and antihistaminic III generation drugs were the most common treatment ([Table 2](#t0002){ref-type="table"}).

###### 

Therapeutic preferences in the pharmacotherapy for asthma, COPD or allergic rhinitis and concomitant diseases

  Variable                                                                                          Rare         Frequent     Most common
  ------------------------------------------------------------------------------------------------- ------------ ------------ -------------
  Drugs used in patients with asthma and concomitant hypertension, *n* (%):                                                   
   Short-acting inhaled β~2~-mimetic                                                                93 (29.0)    137 (43.0)   89 (28.0)
   Inhaled glucocorticosteroids                                                                     41 (13.0)    46 (14.0)    233 (73.0)
   Antileukotriene                                                                                  76 (24.0)    172 (54.0)   70 (22.0)
   Long-acting inhaled β~2~-mimetic                                                                 64 (20.0)    153 (48.0)   102 (32.0)
   Long-acting anticholinergic                                                                      204 (64.0)   99 (31.0)    16 (5.0)
   Theophylline                                                                                     201 (63.0)   108 (34.0)   9 (3.0)
   Oral glucocorticosteroids                                                                        230 (72.0)   86 (27.0)    3 (1.0)
   Antibody anti-IgE                                                                                290 (91.0)   19 (6.0)     9 (3.0)
  Drugs used in patients with asthma and concomitant type 2 diabetes, *n* (%):                                                
   Short-acting inhaled β~2~-mimetic                                                                86 (27.0)    115 (36.0)   118 (37.0)
   Inhaled glucocorticosteroids                                                                     61 (19.0)    57 (18.0)    249 (78.0)
   Antileukotriene                                                                                  76 (24.0)    169 (53.0)   73 (23.0)
   Long-acting inhaled β~2~-mimetic                                                                 61 (19.0)    137 (43.0)   121 (38.0)
   Long-acting anticholinergic                                                                      223 (70.0)   80 (25.0)    16 (5.0)
   Theophylline                                                                                     195 (61.0)   115 (36.0)   9 (3.0)
   Oral glucocorticosteroids                                                                        268 (84.0)   51 (16.0)    0 (0)
   Antibody anti-IgE                                                                                287 (90.0)   16 (5.0)     16 (5.0)
  Drugs used in patients with asthma and concomitant cardiovascular diseases, *n* (%):                                        
   Short-acting inhaled β~2~-mimetic                                                                93 (29.0)    137 (43.0)   89 (28.0)
   Inhaled glucocorticosteroids                                                                     35 (11.0)    38 (12.0)    246 (77.0)
   Antileukotriene                                                                                  80 (25.0)    175 (55.0)   64 (20.0)
   Long-acting inhaled β~2~-mimetic                                                                 51 (16.0)    166 (52.0)   102 (32.0)
   Long-acting anticholinergic                                                                      198 (62.0)   105 (33.0)   16 (5.0)
   Theophylline                                                                                     214 (67.0)   99 (31.0)    6 (2.0)
   Oral glucocorticosteroids                                                                        258 (81.0)   57 (18.0)    3 (1.0)
   Antibody anti-IgE                                                                                281 (88.0)   26 (8.0)     13 (4.0)
  Drugs used in patients with asthma and concomitant sleep apnoea, *n* (%):                                                   
   Short-acting inhaled β~2~-mimetic                                                                83 (26.0)    108 (34.0)   128 (40.0)
   Inhaled glucocorticosteroids                                                                     54 (17.0)    41 (13.0)    223 (70.0)
   Antileukotriene                                                                                  93 (29.0)    160 (50.0)   67 (21.0)
   Long-acting inhaled β~2~-mimetic                                                                 54 (17.0)    134 (42.0)   131 (41.0)
   Long-acting anticholinergic                                                                      204 (64.0)   89 (28.0)    26 (8.0)
   Theophylline                                                                                     169 (53.0)   137 (43.0)   13 (4.0)
   Oral glucocorticosteroids                                                                        242 (76.0)   73 (23.0)    3 (1.0)
   Antibody anti-IgE                                                                                284 (89.0)   19 (6.0)     16 (5.0)
  Drugs used in patients with COPD and concomitant hypertension, *n* (%):                                                     
   Short-acting inhaled β~2~-mimetic                                                                102 (32.0)   102 (32.0)   115 (36.0)
   Inhaled glucocorticosteroids                                                                     70 (22.0)    172 (54.0)   76 (24.0)
   Antileukotriene                                                                                  192 (60.0)   108 (34.0)   19 (6.0)
   Long-acting inhaled β~2~-mimetic                                                                 64 (20.0)    115 (36.0)   140 (44.0)
   Long-acting anticholinergic                                                                      102 (32.0)   86 (27.0)    131 (41.0)
   Theophylline                                                                                     179 (56.0)   128 (40.0)   13 (4.0)
   Oral glucocorticosteroids, n (%)                                                                 258 (81.0)   57 (18.0)    3 (1.0)
  Drugs used in patients with COPD and concomitant type 2 diabetes, *n* (%):                                                  
   Short-acting inhaled β~2~-mimetic                                                                99 (31.0)    115 (36.0)   105 (33.0)
   Inhaled glucocorticosteroids                                                                     89 (28.0)    160 (50.0)   70 (22.0)
   Antileukotriene                                                                                  210 (66.0)   80 (25.0)    29 (9.0)
   Long-acting inhaled β~2~-mimetic                                                                 54 (17.0)    93 (29.0)    172 (54.0)
   Long-acting anticholinergic                                                                      102 (32.0)   89 (28.0)    128 (40.0)
   Theophylline                                                                                     265 (83.0)   51 (16.0)    3 (1.0)
   Oral glucocorticosteroids                                                                        300 (94.0)   19 (6.0)     0 (0)
  Drugs used in patients with COPD and concomitant cardiovascular diseases, *n* (%):                                          
   Short-acting inhaled β~2~-mimetic                                                                99 (31.0)    112 (35.0)   108 (34.0)
   Inhaled glucocorticosteroids                                                                     83 (26.0)    166 (52.0)   70 (22.0)
   Antileukotriene                                                                                  201 (63.0)   83 (26.0)    35 (11.0)
   Long-acting inhaled β~2~-mimetic                                                                 61 (19.0)    118 (37.0)   140 (44.0)
   Long-acting anticholinergic                                                                      108 (34.0)   73 (23.0)    137 (43.0)
   Theophylline                                                                                     195 (61.0)   118 (37.0)   6 (2.0)
   Oral glucocorticosteroids                                                                        271 (85.0)   46 (14.0)    3 (1.0)
  Drugs used in patients with COPD and concomitant sleep apnoea, *n* (%):                                                     
   Short-acting inhaled β~2~-mimetic                                                                93 (29.0)    115 (36.0)   112 (35.0)
   Inhaled glucocorticosteroids                                                                     86 (27.0)    147 (46.0)   86 (27.0)
   Antileukotriene                                                                                  217 (68.0)   83 (26.0)    19 (6.0)
   Long-acting inhaled β~2~-mimetic                                                                 51 (16.0)    115 (36.0)   153 (48.0)
   Long-acting anticholinergic                                                                      83 (26.0)    80 (25.0)    156 (49.0)
   Theophylline                                                                                     175 (55.0)   124 (39.0)   19 (6.0)
   Oral glucocorticosteroids                                                                        274 (86.0)   38 (12.0)    6 (2.0)
  Drugs used in patients with allergic rhinitis and concomitant hypertension, *n* (%):                                        
   Antihistamine I generation                                                                       249 (78.0)   61 (19.0)    9 (3.0)
   Antihistamine II generation                                                                      90 (30.0)    131 (41.0)   93 (29.0)
   Antihistamine III generation                                                                     76 (24.0)    115 (36.0)   128 (40.0)
   Drugs reducing nasal congestion                                                                  195 (61.0)   112 (35.0)   13 (4.0)
   Nasal glucocorticosteroids                                                                       61 (19.0)    76 (24.0)    182 (57.0)
  Drugs used in patients with allergic rhinitis and concomitant type 2 diabetes, *n* (%):                                     
   Antihistamine I generation                                                                       252 (79.0)   57 (18.0)    9 (3.0)
   Antihistamine II generation                                                                      112 (35.0)   140 (44.0)   67 (21.0)
   Antihistamine III generation                                                                     73 (23.0)    115 (36.0)   131 (41.0)
   Drugs reducing nasal congestion                                                                  172 (54.0)   128 (40.0)   19 (6.0)
   Nasal glucocorticosteroids                                                                       207 (65.0)   48 (15.0)    64 (20.0)
  Drugs used in patients with allergic rhinitis and concomitant cardiovascular diseases, *n* (%):                             
   Antihistamine I generation                                                                       281 (88.0)   32 (10.0)    6 (2.0)
   Antihistamine II generation                                                                      118 (37.0)   128 (40.0)   73 (23.0)
   Antihistamine III generation                                                                     73 (23.0)    128 (40.0)   118 (37.0)
   Drugs reducing nasal congestion                                                                  179 (56.0)   124 (39.0)   16 (5.0)
   Nasal glucocorticosteroids                                                                       61 (19.0)    86 (27.0)    172 (54.0)
  Drugs used in patients with allergic rhinitis and concomitant sleep apnoea, *n* (%):                                        
   Antihistamine I generation                                                                       252 (79.0)   54 (17.0)    13 (4.0)
   Antihistamine II generation                                                                      134 (42.0)   128 (40.0)   57 (18.0)
   Antihistamine III generation                                                                     83 (26.0)    115 (36.0)   121 (38.0)
   Drugs reducing nasal congestion                                                                  160 (50.0)   134 (42.0)   26 (8.0)
   Nasal glucocorticosteroids                                                                       61 (19.0)    70 (22.0)    188 (59.0)

Study group characteristics {#sec4.4}
---------------------------

The study group was dominated by urban residents with vocational and secondary education, suffering from asthma. Characteristics of the surveyed population are summarized in [Table 3](#t0003){ref-type="table"}.

###### 

Study group characteristics (*N* = 11,310)

  Parameter                      Result
  ------------------------------ --------------
  Age, mean ± SD \[years\]       49.7 ±19.6
  Gender, *n* (%):               
   Male                          5,497 (48.6)
   Female                        5,813 (51.4)
  Education, *n* (%):            
   Primary                       1,482 (13.1)
   Vocational                    3,608 (31.9)
   Secondary                     3,992 (35.3)
   Higher                        2,228 (19.7)
  Place of residence, *n* (%):   
   Rural                         2,895 (25.6)
   Town ≤ 200 000 residents      6,662 (58.9)
   City \> 200 000 residents     1,753 (15.5)
  Primary diagnosis, *n* (%):    
   Asthma                        5,492 (48.6)
   COPD                          2,868 (25.3)
   Allergic rhinitis             2,950 (26.1)

Among the patients with asthma, 61.8% were diagnosed with controlled asthma. Uncontrolled asthma occurred in 1.3% of the population. Among the patients suffering from COPD, 48.0% were in the B category and 25.5% in the C category according to the GOLD recommendation. Among the patients with allergic rhinitis, 61.6% suffered from the disease's moderate and 32.6% from mild intensity ([Table 4](#t0004){ref-type="table"}).

###### 

Clinical characteristics of study subgroups

  Parameter                                                                                                   Asthma (*N* = 5492)   COPD (*N* = 2868)   Allergic rhinitis (*N* = 2950)
  ----------------------------------------------------------------------------------------------------------- --------------------- ------------------- --------------------------------
  Duration of the disease, *n* (%):                                                                                                                     
   \< 3 months                                                                                                71 (1.3)              20 (0.7)            12 (0.4)
   3--6 months                                                                                                71 (1.3)              86 (3.0)            32 (1.1)
   6--12 months                                                                                               132 (2.4)             43 (1.5)            106 (3.6)
   1--2 years                                                                                                 434 (7.9)             138 (4.8)           212 (7.2)
   2--3 years                                                                                                 533 (9.7)             370 (12.9)          448 (15.2)
   3--4 years                                                                                                 0 (0)                 0 (0)               32 (1.1)
   4--5 years                                                                                                 895 (16.3)            677 (23.6)          555 (18.8)
   \> 5 years                                                                                                 3,335 (60.9)          1,534 (53.5)        1,549 (52.5)
  Severity of asthma according to GINA, *n* (%):                                                                                                        
   Controlled asthma                                                                                          3394 (61.8)           --                  --
   Partially controlled asthma                                                                                2,027 (36.9)          --                  --
   Uncontrolled asthma                                                                                        71 (1.3)              --                  --
  Severity of COPD according to GOLD, *n* (%):                                                                                                          
   Category A                                                                                                 --                    338 (11.8)          --
   Category B                                                                                                 --                    1,377 (48.0)        --
   Category C                                                                                                 --                    731 (25.5)          --
   Category D                                                                                                 --                    424 (14.8)          --
  Severity of allergic rhinitis, *n* (%):                                                                                                               
   Mild                                                                                                       --                    --                  962 (32.6)
   Moderate                                                                                                   --                    --                  1,817 (61.6)
   Severe                                                                                                     --                    --                  171 (5.8)
  Treatment used for asthma, *n* (%):                                                                                                                   
   Short-acting inhaled β~2~-mimetic                                                                          1,307 (23.8)          --                  --
   Inhaled glucocorticosteroids                                                                               1,560 (28.4)          --                  --
   Antileukotriene                                                                                            972 (17.7)            --                  --
   Long-acting inhaled β~2~-mimetic                                                                           1,400 (25.5)          --                  --
   Long-acting anticholinergic                                                                                93 (1.7)              --                  --
   Theophylline                                                                                               121 (2.2)             --                  --
   Oral glucocorticosteroids                                                                                  33 (0.6)              --                  --
   Antibody anti-IgE                                                                                          11 (0.2)              --                  --
  Treatment used for COPD, *n* (%):                                                                                                                     
   Anticholinergic                                                                                            --                    576 (20.1)          --
   Short-acting inhaled β~2~-mimetic                                                                          --                    424 (14.8)          --
   Inhaled glucocorticosteroids                                                                               --                    562 (19.6)          --
   Long-acting inhaled β~2~-mimetic                                                                           --                    843 (29.4)          --
   Theophylline                                                                                               --                    330 (11.5)          --
   Oral glucocorticosteroids                                                                                  --                    43 (1.5)            --
   Indacaterol                                                                                                --                    69 (2.4)            --
   An inhibitor of phosphodiesterase 4                                                                        --                    20 (0.7)            --
  Treatment used for allergic rhinitis, *n* (%):                                                                                                        
   Antihistamine I generation                                                                                 --                    --                  68 (2.3)
   Antihistamine II generation                                                                                --                    --                  560 (19.0)
   Antihistamine III generation                                                                               --                    --                  723 (24.5)
   Drugs reducing nasal congestion                                                                            --                    --                  115 (3.9)
   Nasal glucocorticosteroids                                                                                 --                    --                  1,484 (50.3)
  Concomitant diseases, *n* (%)                                                                               3,213 (58.5)          2,317 (80.8)        1,369 (46.4)
   Allergic rhinitis, *n* (%)                                                                                 692 (12.6)            20 (0.7)            --
   Allergic conjunctivitis, *n* (%)                                                                           373 (6.8)             43 (1.5)            183 (6.2)
   Chronic sinusitis, *n* (%)                                                                                 143 (2.6)             52 (1.8)            204 (6.9)
   Gastroesophageal reflux disease, *n* (%)                                                                   632 (11.5)            508 (17.7)          408 (13.8)
   Obesity, *n* (%)                                                                                           313 (5.7)             244 (8.5)           139 (4.7)
   Overweight, *n* (%)                                                                                        533 (9.7)             582 (20.3)          236 (8.0)
   Type 1 diabetes, *n* (%)                                                                                   49 (0.9)              149 (5.2)           41 (1.4)
   Type 2 diabetes, *n* (%)                                                                                   500 (9.1)             665 (23.2)          118 (4.0)
   Sleep apnoea syndrome, *n* (%)                                                                             49 (0.9)              138 (4.8)           32 (1.1)
   Depression, *n* (%)                                                                                        170 (3.1)             138 (4.8)           41 (1.4)
   Hypertension, *n* (%)                                                                                      1444 (26.3)           1,672 (58.3)        525 (17.8)
   Ischemic heart disease, *n* (%)                                                                            341 (6.2)             652 (21.8)          41 (1.4)
  Factors that influence the choice of the treatment used for asthma or COPD or allergic rhinitis, *n* (%):                                             
   Patient age                                                                                                2,911 (53.0)          1,830 (63.8)        2,021 (68.5)
   GINA or GOLD recommendations or allergic rhinitis taking into account the severity of the disease          5,162 (94.0)          2,699 (94.1)        2,864 (97.1)
   Occurrence of concomitant diseases                                                                         2,060 (37.5)          1,554 (54.2)        1,572 (53.3)
   Interactions with other drugs                                                                              2,158 (39.3)          1,417 (49.4)        1,528 (51.8)
   Impact on quality of life                                                                                  2,642 (48.1)          1,661 (57.9)        1,956 (66.3)
   Price of the drug                                                                                          1,032 (18.8)          221 (7.7)           941 (31.9)

The most common treatment for asthma was inhaled glucocorticosteroids and long-acting β~2~-mimetics. For COPD the treatment most commonly involved inhaled long-acting β~2~-mimetics, cholinolytic drugs and inhaled glucocorticosteroids, whereas for allergic rhinitis -- nasal glucocorticosteroids ([Table 4](#t0004){ref-type="table"}).

Comorbidities were reported in 58.5% of patients with asthma, 80.8% of patients with COPD and 46.6% of patients with allergic rhinitis ([Table 4](#t0004){ref-type="table"}).

The most common comorbidities in patients with asthma included hypertension (26.3%), allergic rhinitis (12.6%) and the gastroesophageal reflux disease (11.5%), among patients with COPD it was hypertension (58.3%), type 2 diabetes (23.2%), ischemic heart disease (21.8%) and overweight (20.3%) whereas in patients with allergic rhinitis -- hypertension (17.8%) and the gastroesophageal reflux disease (13.8%).

The most important factors influencing the selection of the used asthma treatment were the GINA recommendations taking into account the severity of the disease (94.0%), patient age (53.0%) and the impact on the quality of life (48.1%). For COPD, the most important factors included the GOLD recommendations taking into account the severity of the disease (94.1%), patient age (63.8%) and the impact on the quality of life (57.9%). For allergic rhinitis, such factors involved the recommendations taking into account the severity of the disease (97.1%), patient age (68.5%) and the impact on the quality of life (66.3%). The comorbidities and drug interactions were the least common factor taken into consideration in patients diagnosed with asthma (37.5% and 39.3%, respectively) -- [Table 4](#t0004){ref-type="table"}.

Discussion {#sec5}
==========

Doctors participating in this study most commonly declared the use of inhaled glucocorticosteroids and then short-acting β~2~-agonists for asthma treatment. This strategy is in accordance with grade 2 therapy and secondly with grade 1 therapy recommended by GINA \[[@cit0041]\]. It suggests that subjects with mild asthma dominated among their patients when initiating the treatment. This hypothesis is supported by the results assessing the factors determining the therapeutic decisions among which the most important were GINA recommendations taking into consideration the severity of the disease. It should be noted that inhaled glucocorticosteroids were most commonly used for asthma treatment regardless of the co-occurrence of hypertension, type 2 diabetes, cardiovascular diseases and sleep apnoea. However, their use in patients with comorbidities slightly decreased in favour of long-acting β~2~-mimetics. It is interesting as this strategy is not in accordance with grade 3 therapy recommended by GINA \[[@cit0041]\]. Thus, these decisions cannot be explained by asthma exacerbations. On the other hand, inhaled glucocorticosteroids are used in low doses and their absorption from the respiratory tract into the systemic circulation is low. Therefore, their impact on the course of comorbidities is negligible. Further studies are necessary to explain the factors that influenced these therapeutic preferences.

When comparing the physicians' declarations with the results in the study group of patients with asthma, some differences appear concerning the use of long-acting β~2~-mimetics that were more commonly prescribed than short-acting inhaled β~2~-mimetics. The comorbidities occurred in 58.5% of patients with asthma, with the most common one being hypertension. The most important factors indicated by the physician as justification of the treatment for asthma were the GINA recommendation taking into account the severity of the disease, whereas comorbidities were the least important factor taken into account.

In the population of patients with COPD, doctors most commonly declared the use of inhaled long-acting β~2~-agonist and cholinolytics, followed by inhaled short-acting β~2~-agonists. This selection of drugs is recommended by the GOLD strategy as the treatment of first choice in B--D class COPD \[[@cit0042]\]. The questionnaire did not include questions concerning the choice of drugs in relation to the severity of the disease. However, our results suggest that among the study population, patients with this stage of the disease were dominant. This hypothesis is supported by the results assessing factors determining the therapeutic decisions among which the most important factor was the GOLD recommendations tailored to the severity of the disease. It should be noted that inhaled long-acting β~2~-mimetics were most commonly prescribed in COPD treatment regardless of the co-occurrence of hypertension, type 2 diabetes, cardiovascular diseases and sleep apnoea. However, in groups with comorbidities, an increased use of inhaled short-acting β~2~-mimetics in comparison to the declaration was noted for general COPD populations. This may indicate frequent occurrence of dyspnoea among patients with comorbidities. The hypothesis is supported by the observation that COPD exacerbations are most common among patients with comorbidities such as diabetes and cardiovascular diseases \[[@cit0029]\].

In the observed group of patients, the most common COPD medications were inhaled long-acting β~2~-mimetics, cholinolytic drugs and inhaled glucocorticosteroids. The comorbidities occurred in 80.8% of patients with COPD, with the most common one being hypertension. The most important factors influencing the choice of asthma treatment were Gina recommendations tailored to the severity of the disease. It is worth mentioning that comorbidities were not among the three most important factors influencing the therapeutic decisions. However, a relatively common use of inhaled glucocorticosteroids suggests their use for the prevention of exacerbations in COPD patients at high risk of exacerbation, which is in accordance with GOLD recommendations \[[@cit0042]\].

In the population of patients with allergic rhinitis, doctors most commonly declared the use of nasal glucocorticosteroids and antihistamine III generation drugs. Antihistamine drugs, according to recommendations, are the first-line treatment of allergic rhinitis together with preparations that reduce nasal congestion. However, an additional use of glucocorticosteroids is recommended when the therapy is not effective \[[@cit0043]\]. Thus, the declared decisions are partially inconsistent with the recommendations. On the other hand, glucocorticosteroids are most effective in removing all symptoms of allergic rhinitis \[[@cit0043]\]. Indeed, the doctors determined effectiveness as the most important factor in the decision-making process. It should be noted that the choice of nasal glucocorticosteroids and antihistamine III generation drugs was not affected by the occurrence of comorbidities.

The frequency of nasal glucocorticosteroids prescribed in study patients with allergic rhinitis is in line with doctors' preferences. The most important factors influencing the selection of the treatment for allergic rhinitis were the recommendations tailored to the severity of the disease. Whereas comorbidities (reported in 46.6% of patients) were not among the three most important factors influencing therapeutic choices.

Conclusions {#sec6}
===========

The co-occurrence of chronic diseases was most frequent among patients diagnosed with COPD. The treatment of asthma, COPD and allergic rhinitis is consistent with international recommendations and the occurrence of concomitant diseases did not significantly influence the therapeutic preferences and decisions.
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